Elevance Health (ELV) reported that it surpassed its Q1 earnings and revenue estimates. It sees lower-than-expected medical costs, contributing to its positive results. These achievements led Barclays and Argus to increase their price targets to $522 and $465, respectively, reflecting investor confidence. Despite accusations of an influx in unusual volume, ELV maintains its 2025 outlook and solidifies its growth strategy, driven by Medicaid and Carelon development, not yet fully appreciated by the market. ELV's management confirms that they use debt sensibly, with the company’s stock outperforming its underlying earnings growth over the last five years. It reportedly plans to tackle a shareholder proposal on diversity and inclusion reporting. Concerning the future, ELV’s implied volatility surge signals increased market sentiment and trading activity, with the medical care provider continuing to reward shareholders with regular dividends. Investors from Wall Street view ELV as one of the best medical and telehealth stocks to buy.
Elevance Health ELV News Analytics from Thu, 17 Oct 2024 07:00:00 GMT to Fri, 25 Apr 2025 13:50:27 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 4
